XTXiaofan Tian

Xiaofan Tian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaofan Tian has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers

    by Xiaofan Tian, Habib Esmaeili, David Minich, Friedeborg Seitz, Philipp M. Roessner, Sven Wind, Rolf Grempler, Guanfa Gan, Tom S. Chan, Mazyar Mahmoudi, et al.

    Introduction: Zongertinib (BI 1810631) is a potent, selective, and epidermal growth factor receptor (EGFR) wild‐type sparing human epidermal growth factor receptor 2 (HER2) inhibitor. Based on in vitro data, the oxidative hepatic metabolism of zongertinib is principally driven by cytochrome P450 (CYP) 3A4/5. Therefore, zongertinib may be affected by strong CYP3A inducers, like carbamazepine.Objective: This study aimed to investigate the effect of multiple oral doses of carbamazepine on the pharmacokinetics of a single oral dose of zongertinib in healthy male subjects.Methods: This open‐label, two‐period, fixed‐sequence clinical drug–drug interaction study examined the pharmacokinetics of a single 60‐mg oral dose of zongertinib in the absence or presence of multiple oral doses of carbamazepine. The extent of drug–drug interaction was estimated using the adjusted geometric mean ratios (and 90% confidence intervals [CIs]) for the test treatment (zongertinib in the presence of carbamazepine) versus the reference treatment (zongertinib alone) for areas under the plasma concentration–time curve from time 0 to infinity and to the last quantifiable time point (AUC0–∞, AUC0–tz) and maximum measured plasma concentration (Cmax).Results: Sixteen subjects (all Caucasian males) received zongertinib alone in Study Period 1, and 15 of them received both zongertinib and carbamazepine in Study Period 2. Upon co‐administration with carbamazepine in Study Period 2, AUC0–∞ and AUC0–tz of zongertinib were both reduced to 36.5% (90% CI: 32.0%–41.6% for AUC0–∞ and 31.9%–41.7% for AUC0–tz). The Cmax of zongertinib was reduced to 56.4% (90% CI: 45.1%–70.6%).Conclusion: Zongertinib exposure was reduced by 63.5% when coadministered with the strong CYP3A inducer, carbamazepine.


  • Impact of Chronic Inflammatory Diseases on Clinical Pharmacokinetics of Antibody‐Based Therapeutic Proteins

    by Xiaofan Tian, Yichao Yu, Harshith Neeli, Dilara Jappar

    Antibody‐based therapeutic proteins (TPs) emerged as a promising therapeutic modality for chronic inflammatory diseases. During clinical development, the impact of disease on pharmacokinetics (PK) should be carefully considered to reliably extrapolate PK from healthy volunteers (HVs) in early‐phase studies to patients in later‐phase studies. This paper aimed to provide an overview of the impact of chronic inflammatory diseases on the PK of antibody‐based TPs. A literature search was conducted on Drugs@FDA and PubMed, yielding 30 TPs with author‐drawn conclusions about PK differences between HVs and patients with inflammatory diseases. Nine out of 30 TPs suggested PK differences in patients with inflammatory diseases compared with HVs, and patients mostly appeared to have higher drug clearance or lower drug exposure compared with HVs. However, the remaining 21 TPs appeared to have no apparent PK differences between patients and HVs. Based on ratios of reported drug clearance in patients vs. HVs (N: 31 ratios for 22 TPs), the difference in TP clearance due to inflammatory diseases did not exceed twofold (mean clearance ratio: 1.23; standard deviation: 0.25), with the most noticeable difference (>50% higher clearance) observed in patients with inflammatory bowel diseases and rheumatoid arthritis. Covariate assessment in published population PK models of TPs revealed that higher baseline C‐reactive proteins and lower baseline albumin levels tend to be correlated with higher TP clearance. Future investigation is necessary to further elucidate the mechanism behind the inflammatory disease‐mediated PK differences.


  • Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches

    by Yunjung H Shin, Xiaofan Tian, Jiyeon J Park, Gee Y (Geeny) Kim, Emily Aboujaoude, Marc G Sturgill

    The most common adverse event associated with chimeric antigen receptor T-cell therapy is cytokine release syndrome, which is characterized by fever, hypoxia, and hypotension in varying degrees of severity. In severe cases, cytokine release syndrome can result in life-threatening symptoms such as multi-organ failure. The widely accepted first-line therapy for cytokine release syndrome management is tocilizumab with or without corticosteroids, but there is very limited guidance on the proper management of patients unresponsive to this regimen. There are emerging strategies that target cytokine release syndrome through novel mechanisms, showing promise in treating or preventing severe cytokine release syndrome. Although further clinical investigation is necessary to assess the applicability of the emerging approaches, these exploratory therapies may shape the future landscape of chimeric antigen receptor T-cell induced cytokine release syndrome management. This review article provides a comprehensive overview of the current and emerging therapies for the management of chimeric antigen receptor T-cell induced cytokine release syndrome, especially cases that are refractory to tocilizumab and steroids.